FAQ: What Does the Medicare GLP-1 Bridge Mean for Pharma?

Despite reshaping obesity treatment, GLP-1 receptor agonists have remained out of reach for Medicare Part D beneficiaries seeking coverage for weight loss. Federal law prohibits Medicare from covering drugs solely for weight loss, meaning GLP-1s are only reimbursed under Part D for other approved indications, like type 2 diabetes, cardiovascular risk reduction, MASH, or sleep apnea.¹ Despite these constraints, the commercial consequence has been significant: Medicare logged $27.5 billion in gross GLP-1 spending across 21.8 million claims in 2024, entirely under FDA-approved indications other than obesity.¹ A new CMS demonstration is now attempting to expand that eligibility, at least temporarily.

What Is the Medicare GLP-1 Bridge and Why Does It Exist?

The Medicare GLP-1 Bridge is a short-term CMS demonstration providing eligible Part D beneficiaries with access to certain GLP-1 drugs for obesity at a flat $50 monthly copay, running July 1, 2026 through December 31, 2027.² Because current statute bars Part D from covering drugs used solely for weight loss, CMS cannot add GLP-1s to formularies directly; instead, the agency is acting under Section 402 demonstration authority, which permits time-limited testing of "changes in methods of payment or reimbursement.”² The program was also designed to collect GLP-1 utilization data to share with Part D plan sponsors ahead of potential implementation of the longer-term BALANCE Model.²

What Does the Bridge Mean for Patient Access — and What Are Its Limits?

The Bridge expands GLP-1 access for a Medicare population that has been categorically locked out of obesity coverage, and the $50 monthly copay represents a substantial reduction from higher cash-pay prices for branded agents. For eligible beneficiaries who clear the clinical and plan-type criteria, the demonstration reduces a significant financial barrier to initiating therapy. But the access picture is narrower than the headline suggests. Clinical thresholds, plan-type exclusions, a covered product list limited to three branded drugs, and the LIS cost-sharing carveout all constrain who can actually benefit. The Bridge also runs through December 31, 2027, and with the BALANCE Model indefinitely delayed, there is no guaranteed coverage pathway inside the program when the demonstration ends.

Register for free in 30 seconds to continue reading this exclusive member's-only content.

References

1. KFF, "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge," May 11, 2026 https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
2. CMS, Medicare GLP-1 Bridge, cms.gov (updated May 6, 2026) https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge